Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.

Carrasco-Triguero M, Yi JH, Dere R, Qiu ZJ, Lei C, Li Y, Mahood C, Wang B, Leipold D, Poon KA, Kaur S.

Bioanalysis. 2013 May;5(9):1007-23. doi: 10.4155/bio.13.64.

PMID:
23641693
2.

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.

Dere R, Yi JH, Lei C, Saad OM, Huang C, Li Y, Baudys J, Kaur S.

Bioanalysis. 2013 May;5(9):1025-40. doi: 10.4155/bio.13.72.

PMID:
23641694
3.

Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.

Poon KA, Flagella K, Beyer J, Tibbitts J, Kaur S, Saad O, Yi JH, Girish S, Dybdal N, Reynolds T.

Toxicol Appl Pharmacol. 2013 Dec 1;273(2):298-313. doi: 10.1016/j.taap.2013.09.003. Epub 2013 Sep 12.

4.

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.

Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A.

Cancer Chemother Pharmacol. 2012 May;69(5):1229-40. doi: 10.1007/s00280-011-1817-3. Epub 2012 Jan 20.

5.

A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.

Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE.

AAPS J. 2014 Sep;16(5):994-1008. doi: 10.1208/s12248-014-9618-3. Epub 2014 Jun 11.

6.

Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.

Hoofring SA, Lopez R, Hock MB, Kaliyaperumal A, Patel SK, Swanson SJ, Chirmule N, Starcevic M.

Bioanalysis. 2013 May;5(9):1041-55. doi: 10.4155/bio.13.10.

PMID:
23641695
7.

Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

Pillow TH, Tien J, Parsons-Reponte KL, Bhakta S, Li H, Staben LR, Li G, Chuh J, Fourie-O'Donohue A, Darwish M, Yip V, Liu L, Leipold DD, Su D, Wu E, Spencer SD, Shen BQ, Xu K, Kozak KR, Raab H, Vandlen R, Lewis Phillips GD, Scheller RH, Polakis P, Sliwkowski MX, Flygare JA, Junutula JR.

J Med Chem. 2014 Oct 9;57(19):7890-9. doi: 10.1021/jm500552c. Epub 2014 Sep 18.

PMID:
25191794
8.

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.

Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K.

Curr Med Res Opin. 2013 Apr;29(4):405-14. doi: 10.1185/03007995.2013.775113. Epub 2013 Mar 1. Review.

PMID:
23402224
9.

[Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)].

Gonçalves A, Trédan O, Villanueva C, Dumontet C.

Bull Cancer. 2012 Dec;99(12):1183-91. doi: 10.1684/bdc.2012.1669. Review. French.

10.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA.

J Clin Oncol. 2013 Mar 20;31(9):1157-63. doi: 10.1200/JCO.2012.44.9694. Epub 2013 Feb 4. Erratum in: J Clin Oncol. 2013 Aug 10;31(23):2977.

PMID:
23382472
11.

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX.

Clin Cancer Res. 2010 Oct 1;16(19):4769-78. doi: 10.1158/1078-0432.CCR-10-0987. Epub 2010 Aug 30.

12.

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.

Mathew J, Perez EA.

Curr Opin Oncol. 2011 Nov;23(6):594-600. doi: 10.1097/CCO.0b013e32834b895c. Review.

PMID:
21986845
13.

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.

LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX.

Clin Cancer Res. 2011 Oct 15;17(20):6437-47. doi: 10.1158/1078-0432.CCR-11-0762. Review.

14.

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, Holden SN, Modi S.

Cancer. 2012 Dec 1;118(23):5733-40. doi: 10.1002/cncr.27622. Epub 2012 May 30.

15.

Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.

Sapra P, Betts A, Boni J.

Expert Rev Clin Pharmacol. 2013 Sep;6(5):541-55. doi: 10.1586/17512433.2013.827405. Epub 2013 Aug 26. Review.

PMID:
23978126
16.

Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.

[No authors listed]

Med Lett Drugs Ther. 2013 Sep 16;55(1424):75-6. No abstract available.

PMID:
24043217
17.

Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.

Beerli RR, Hell T, Merkel AS, Grawunder U.

PLoS One. 2015 Jul 1;10(7):e0131177. doi: 10.1371/journal.pone.0131177. eCollection 2015.

18.

Ado-trastuzumab emtansine approved for advanced breast cancer.

Traynor K.

Am J Health Syst Pharm. 2013 Apr 1;70(7):562. doi: 10.2146/news130023. No abstract available. Erratum in: Am J Health Syst Pharm. 2013 May 15;70(10):840.

PMID:
23515502
19.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX.

Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776.

20.

Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).

Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, Du X, Saad O, Bowles K, Olsen S, Lewis Phillips GD, Hartley D, Sliwkowski MX, Girish S, Dambach D, Ramakrishnan V.

Clin Cancer Res. 2015 Jan 1;21(1):123-33. doi: 10.1158/1078-0432.CCR-14-2093. Epub 2014 Nov 4.

Supplemental Content

Support Center